{"schema_version":"secwatch.filing_event.v1","accession":"0001079973-24-000486","form_type":"8-K","ticker":"LCTC","cik":"0001493137","company_name":"Lifeloc Technologies, Inc","filed_at":"2024-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.646011+00:00","generated_at":"2026-06-04T03:30:02.864468+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lifeloc reports 2023 revenue $9.33M, net profit $206K vs loss prior year","bullets":["Net revenue $9.330M (+10% YoY); net profit $206K ($0.08 diluted EPS) vs net loss $456K ($0.19 loss) in 2022.","Gross margin improved to 43.3% from 36.3% due to price increases, lower depreciation, easing supply constraints.","R&D investment increased 32% YoY focused on SpinDx 'Lab on a Disk' drug detection platform.","Beta testing of SpinDx delta-9-THC saliva test expected later 2024; commercialization projected 2025.","CEO says supply constraints no longer significant; L-series devices gaining approvals and market penetration."],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-24-000486","json":"https://secwatch.observer/filing/0001079973-24-000486.json","markdown":"https://secwatch.observer/filing/0001079973-24-000486.md","text":"https://secwatch.observer/filing/0001079973-24-000486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1493137/000107997324000486/0001079973-24-000486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1493137/000107997324000486/lclc_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T03:30:02.864468+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a4cef58ac854f02a589cb439f51c139e72888e6","claim":"Lifeloc Technologies, Inc reported fiscal year ended December 31, 2023 results: revenue $9.330 million, net income $206 thousand, EPS $0.08 per diluted share.","evidence_excerpt":"Lifeloc Technologies posted annual net revenue of $9.330 million resulting in a net profit of $206 thousand in 2023, or $0.08 per diluted share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1493137/000107997324000486/0001079973-24-000486-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$9.330 million"},{"label":"Net income","value":"$206 thousand"},{"label":"EPS","value":"$0.08 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}